PMID- 11283124
OWN - NLM
STAT- MEDLINE
DCOM- 20010503
LR  - 20170210
IS  - 0732-183X (Print)
IS  - 0732-183X (Linking)
VI  - 19
IP  - 7
DP  - 2001 Apr 1
TI  - Congestive heart failure after treatment for Wilms' tumor: a report from the 
      National Wilms' Tumor Study group.
PG  - 1926-34
AB  - PURPOSE: We determined the frequency of and risk factors for congestive heart 
      failure following treatment for Wilms' tumor that included doxorubicin. PATIENTS 
      AND METHODS: Flow sheets and medical records were reviewed to identify cases of 
      congestive heart failure in a cohort of patients treated on National Wilms' Tumor 
      Studies (NWTS)-1, -2, -3, and -4. The frequency of congestive heart failure was 
      estimated using the Kaplan-Meier method. A case-control study was conducted to 
      determine the relationship among cumulative doxorubicin dose, site(s), total dose 
      of abdominal and thoracic irradiation, sex, and the frequency of congestive heart 
      failure. RESULTS: The cumulative frequency of congestive heart failure was 4.4% 
      at 20 years after diagnosis among patients treated initially with doxorubicin and 
      17.4% at 20 years after diagnosis among those treated with doxorubicin for their 
      first or subsequent relapse of Wilms' tumor. The relative risk (RR) of congestive 
      heart failure was increased in females (RR = 4.5; P =.004) and by cumulative 
      doxorubicin dose (RR = 3.3/100 mg/m(2); P <.001), lung irradiation (RR = 1.6/10 
      Gy; P =.037), and left abdominal irradiation (RR = 1.8/10 Gy; P =.013). 
      CONCLUSION: We conclude that congestive heart failure is a risk of treatment with 
      doxorubicin for Wilms' tumor. Additional follow-up of those children treated on 
      NWTS-4 will be necessary to determine if the decrease in dose to 150 mg/m(2) 
      significantly reduces this risk.
FAU - Green, D M
AU  - Green DM
AD  - Department of Pediatrics, Roswell Park Cancer Institute, Buffalo, NY 14263, USA. 
      daniel.green@roswellpark.org
FAU - Grigoriev, Y A
AU  - Grigoriev YA
FAU - Nan, B
AU  - Nan B
FAU - Takashima, J R
AU  - Takashima JR
FAU - Norkool, P A
AU  - Norkool PA
FAU - D'Angio, G J
AU  - D'Angio GJ
FAU - Breslow, N E
AU  - Breslow NE
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Clin Oncol
JT  - Journal of clinical oncology : official journal of the American Society of 
      Clinical Oncology
JID - 8309333
RN  - 0 (Antibiotics, Antineoplastic)
RN  - 0 (Antineoplastic Agents)
RN  - 80168379AG (Doxorubicin)
SB  - IM
CIN - J Clin Oncol. 2003 Jun 15;21(12):2447-8. PMID: 12805354
MH  - Actuarial Analysis
MH  - Antibiotics, Antineoplastic/*adverse effects
MH  - Antineoplastic Agents/*adverse effects
MH  - Case-Control Studies
MH  - Child
MH  - Child, Preschool
MH  - Cohort Studies
MH  - Combined Modality Therapy/adverse effects
MH  - Dose-Response Relationship, Drug
MH  - Doxorubicin/*adverse effects
MH  - Female
MH  - Heart Failure/*chemically induced/epidemiology
MH  - Humans
MH  - Infant
MH  - Infant, Newborn
MH  - Logistic Models
MH  - Male
MH  - Radiotherapy/adverse effects
MH  - Risk
MH  - Sex Distribution
MH  - United States/epidemiology
MH  - Wilms Tumor/*drug therapy
EDAT- 2001/04/03 10:00
MHDA- 2001/05/22 10:01
CRDT- 2001/04/03 10:00
PHST- 2001/04/03 10:00 [pubmed]
PHST- 2001/05/22 10:01 [medline]
PHST- 2001/04/03 10:00 [entrez]
AID - 10.1200/JCO.2001.19.7.1926 [doi]
PST - ppublish
SO  - J Clin Oncol. 2001 Apr 1;19(7):1926-34. doi: 10.1200/JCO.2001.19.7.1926.